Background to service. 2.1 The investment made by the NHS in medicines is for the explicit purpose of delivering health gain to the population. For this investment to bring the best possible outcomes for the people who are prescribed these medicines, pharmaceutical care of the correct quality has to be delivered reliably, safely, effectively and efficiently. The 2011 regulations to the National Health Service (Pharmaceutical Services) (Scotland) Act, places a duty on Boards to secure adequate pharmaceutical care services for the patients within their boundaries. Where medicines are prescribed by secondary care services to outpatients, it may be appropriate for the specified pharmaceutical care to be provided by community pharmacy or homecare. The placement of community pharmacies and their integration within the local healthcare system may mean that they are the preferred route of service provision. 2.2 Pharmaceutical Care Services, provided by community pharmacy, for patients receiving medicines supervised by secondary care has a number of advantages over traditional homecare services: Service provision is more likely to be fully integrated with other local services delivered within the local healthcare system. Access by vulnerable populations is facilitated, including those with less stable lifestyles and the homeless. Effective communication is promoted between community pharmacy, general practice and the secondary care service. Such provision supports and accelerates familiarity with use of these newer medicines within the community setting. Ensuring that patients’ medicines are provided within the context of other medicines prescribed in primary care and the pharmaceutical care needs of the patient. Supports the validity and reliability of the community pharmacy held pharmaceutical care record. Enables assessment of patients’ needs for compliance support and delivery of enhanced support where required as part of the patient’s clinical management plan. 2.3 The national arrangements to provide pharmaceutical services, that all local NHS pharmacy contractors are obliged to provide, includes provision for the supply of medicines in response to a prescription from secondary care. However, these arrangements allow a pharmacy contractor to source medicines to fulfill a prescription from wherever they see fit, subject to the requirements to deliver a product of suitable quality. For almost all of the medicines to be delivered under this agreement there is a primary care rebate scheme in place. These commercially confidential schemes ensure that the net prices paid by a Health Board for a medicine traditionally supplied by secondary care is the same if it is moved to primary care. In order to access these rebate schemes and for rebates to be paid the medicine supplied must be purchased through distribution arrangements put in place by the manufacturer that has been contracted to supply the product to the NHS, sometimes from a specific wholesaler. NHS Boards will reconcile manufacturers supply data with the reimbursement information from PSD to ensure adherence to these distribution arrangements. Clearly NHS Boards cannot allow the price to be paid for the medicine to exceed that which we would incur in secondary care so this agreement makes a specific requirement on contractors to supply products under this agreement that are sourced as described in each service pack. 2.4 For many outpatient medicines the national arrangements for the provision of pharmaceutical care will be appropriate. However, in supplying a small proportion of these medicines there may be a range of governance related issues that should be considered and addressed to support both the smooth supply of medicines and to facilitate local pharmacists discharging their clinical and professional responsibilities. 2.5 It is useful to ensure that all stakeholders are clear about their responsibilities to one another in pursuit of the provision of medicine supply and pharmaceutical care relating to medicines prescribed by the hospital service to outpatients. It is for this reason that these arrangements are included in this specification. 2.6 This umbrella framework specification outlines the generic elements common to each tier of the service and the requirements that should be met within local agreements.
Appears in 3 contracts
Sources: Service Level Agreement, Service Level Agreement (Sla), Service Level Agreement (Sla)
Background to service.
2.1 The investment made by the NHS in medicines is for the explicit purpose of delivering health gain to the population. For this investment to bring the best possible outcomes for the people who are prescribed these medicines, pharmaceutical care of the correct quality has to be delivered reliably, safely, effectively and efficiently. The 2011 regulations to the National Health Service (Pharmaceutical Services) (Scotland) Act, places a duty on Boards to secure adequate pharmaceutical care services for the patients within their boundaries. Where medicines are prescribed by secondary care services to outpatients, it may be appropriate for the specified pharmaceutical care to be provided by community pharmacy or homecare. The placement of community pharmacies and their integration within the local healthcare system may mean that they are the preferred route of service provision.
2.2 Pharmaceutical Care Services, provided by community pharmacy, for patients receiving medicines supervised by secondary care has a number of advantages over traditional homecare services: • Service provision is more likely to be fully integrated with other local services delivered within the local healthcare system. • Access by vulnerable populations is facilitated, including those with less stable lifestyles and the homeless. • Effective communication is promoted between community pharmacy, general practice and the secondary care service. • Such provision supports and accelerates familiarity with use of these newer medicines within the community setting. • Ensuring that patients’ medicines are provided within the context of other medicines prescribed in primary care and the pharmaceutical care needs of the patient. • Supports the validity and reliability of the community pharmacy held pharmaceutical care record. • Enables assessment of patients’ needs for compliance support and delivery of enhanced support where required as part of the patient’s clinical management plan.
2.3 The national arrangements to provide pharmaceutical services, that all local NHS pharmacy contractors are obliged to provide, includes provision for the supply of medicines in response to a prescription from secondary care. However, these arrangements allow a pharmacy contractor to source medicines to fulfill a prescription from wherever they see fit, subject to the requirements to deliver a product of suitable quality. For almost all of the medicines to be delivered under this agreement there is a primary care rebate scheme in place. These commercially confidential schemes ensure that the net prices paid by a Health Board for a medicine traditionally supplied by secondary care is the same if it is moved to primary care. In order to access these rebate schemes and for rebates to be paid the medicine supplied must be purchased through distribution arrangements put in place by the manufacturer that has been contracted to supply the product to the NHS, sometimes from a specific wholesaler. NHS Boards will reconcile manufacturers supply data with the reimbursement information from PSD to ensure adherence to these distribution arrangements. Clearly NHS Boards cannot allow the price to be paid for the medicine to exceed that which we would incur in secondary care so this agreement makes a specific requirement on contractors to supply products under this agreement that are sourced as described in each service pack.
2.4 For many outpatient medicines the national arrangements for the provision of pharmaceutical care will be appropriate. However, in supplying a small proportion of these medicines there may be a range of governance related issues that should be considered and addressed to support both the smooth supply of medicines and to facilitate local pharmacists discharging their clinical and professional responsibilities.
2.5 It is useful to ensure that all stakeholders are clear about their responsibilities to one another in pursuit of the provision of medicine supply and pharmaceutical care relating to medicines prescribed by the hospital service to outpatients. It is for this reason that these arrangements are included in this specification.
2.6 This umbrella framework specification outlines the generic elements common to each tier of the service and the requirements that should be met within local agreements.
Appears in 1 contract
Sources: Service Level Agreement (Sla)
Background to service. 2.1 The investment made by the NHS in medicines is for the explicit purpose of delivering health gain to the population. For this investment to bring the best possible outcomes for the people who are prescribed these medicines, pharmaceutical care of the correct quality has to be delivered reliably, safely, effectively and efficiently. The 2011 regulations to the National Health Service (Pharmaceutical Services) (Scotland) Act, places a duty on Boards to secure adequate pharmaceutical care services for the patients within their boundaries. Where medicines are prescribed by secondary care services to outpatients, it may be appropriate for the specified pharmaceutical care to be provided by community pharmacy or homecare. The placement of community pharmacies and their integration within the local healthcare system may mean that they are the preferred route of service provision.
2.2 Pharmaceutical Care Services, provided by community pharmacy, for patients receiving medicines supervised by secondary care has a number of advantages over traditional homecare services: Service provision is more likely to be fully integrated with other local services delivered within the local healthcare system. Access by vulnerable populations is facilitated, including those with less stable lifestyles and the homeless. Effective communication is promoted between community pharmacy, general practice and the secondary care service. Such provision supports and accelerates familiarity with use of these newer medicines within the community setting. Ensuring that patients’ medicines are provided within the context of other medicines prescribed in primary care and the pharmaceutical care needs of the patient. Supports the validity and reliability of the community pharmacy held pharmaceutical care record. Enables assessment of patients’ needs for compliance support and delivery of enhanced support where required as part of the patient’s clinical management plan.
2.3 The national arrangements to provide pharmaceutical services, that all local NHS pharmacy contractors are obliged to provide, includes provision for the supply of medicines in response to a prescription from secondary care. However, these arrangements allow a pharmacy contractor to source medicines to fulfill a prescription from wherever they see fit, subject to the requirements to deliver a product of suitable quality. For almost all of the medicines to be delivered under this agreement there is a primary care rebate scheme in place. These commercially confidential schemes ensure that the net prices paid by a Health Board for a medicine traditionally supplied by secondary care is the same if it is moved to primary care. In order to access these rebate schemes and for rebates to be paid the medicine supplied must be purchased through distribution arrangements put in place by the manufacturer that has been contracted to supply the product to the NHS, sometimes from a specific wholesaler. NHS Boards will reconcile manufacturers supply data with the reimbursement information from PSD to ensure adherence to these distribution arrangements. Clearly NHS Boards cannot allow the price to be paid for the medicine to exceed that which we would incur in secondary care so this agreement makes a specific requirement on contractors to supply products under this agreement that are sourced as described in each service pack.
2.4 For many outpatient medicines the national arrangements for the provision of pharmaceutical care will be appropriate. However, in supplying a small proportion of these medicines there may be a range of governance related issues that should be considered and addressed to support both the smooth supply of medicines and to facilitate local pharmacists discharging their clinical and professional responsibilities.
2.5 It is useful to ensure that all stakeholders are clear about their responsibilities to one another in pursuit of the provision of medicine supply and pharmaceutical care relating to medicines prescribed by the hospital service to outpatients. It is for this reason that these arrangements are included in this specification.
2.6 This umbrella framework specification outlines the generic elements common to each tier of the service and the requirements that should be met within local agreements.
Appears in 1 contract
Sources: Service Level Agreement (Sla)